| Popis: |
Monoclonal antibodies were produced against the Mirandola strain of canine adenovirus type 1 (CAV-1) and the Manhattan strain of canine adenovirus type 2 (CAV-2). The monoclonal antibodies were used in an indirect fluorescence-antibody (IFA) test and in an vitro virus neutralization (VN) assay to examine several strains of each viral type, including those used for vaccine production in the United States. Out of 36 monoclonal antibodies produced against the Mirandola strain, 18 were type-specific for CAV-1 by IFA and 13 of those neutralized the virus in vitro. The other 18 antibodies bound both CAV-1 and CAV-2 by IFA; however, 7 of those specifically neutralized only CAV-1. The 160 monoclonal antibodies made against the Manhattan strain of CAV-2 yielded 77 type-specific antibodies by IFA, of which 39 neutralized only CAV-2 in vitro. The remaining 83 monoclonal antibodies recognized both CAV-1 and CAV-2 by IFA, with 3 of those neutralizing both viral types, and none neutralizing only CAV-2. Although type 1 CAV could be readily differentiated from type 2 CAV by using monoclonal antibodies in the IFA and VN tests, strains within each type could not be differentiated. Viral proteins were examined by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and radioimmune precipitation (RIP) with hyperimmune dog serum to each type. Monoclonal antibodies were also used in RIP to identify the viral proteins associated with type specificity, group specificity, and neutralization. |
